Seagen
Patents, Design & Utilities
Last updated:
List of all Seagen patents 62 in total
| Status | Patent |
|---|---|
Grant | Utility: Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors Filling date: 6 Sep 2025 Issue date: 8 Jun 2021 |
Grant | Utility: Glycan-interacting compounds and methods of use Filling date: 6 Sep 2025 Issue date: 8 Jun 2021 |
Application | Utility: WEEKLY DOSING REGIMENS FOR ANTI-CD30 VC-PAB-MMAE ANTIBODY DRUG-CONJUGATES Filling date: 6 Sep 2025 Issue date: 13 May 2021 |
Application | Utility: SELECTIVE DRUG RELEASE FROM INTERNALIZED CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS Filling date: 6 Sep 2025 Issue date: 13 May 2021 |
Application | Utility: CD123 Antibodies and Conjugates Thereof Filling date: 6 Sep 2025 Issue date: 6 May 2021 |
Application | Utility: ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS Filling date: 6 Sep 2025 Issue date: 1 Apr 2021 |
Grant | Utility: Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Filling date: 6 Sep 2025 Issue date: 9 Mar 2021 |
Grant | Utility: Hydrophilic antibody-drug conjugates Filling date: 6 Sep 2025 Issue date: 2 Mar 2021 |
Grant | Utility: Weekly dosing regimens for anti-CD30 vc-PAB-MMAE antibody drug-conjugates Filling date: 6 Sep 2025 Issue date: 9 Feb 2021 |
Application | Utility: HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER Filling date: 6 Sep 2025 Issue date: 4 Feb 2021 |
Grant | Utility: Antibody drug conjugates (ADC) that bind to 191P4D12 proteins Filling date: 6 Sep 2025 Issue date: 19 Jan 2021 |
Grant | Utility: Antibody drug conjugates (ADC) that bind to 191P4D12 proteins Filling date: 6 Sep 2025 Issue date: 12 Jan 2021 |
Showing 50 to 62 of 62 patents.